Li, Xi http://orcid.org/0000-0001-9185-7728
Poire, Alfonso
Jeong, Kang Jin
Zhang, Dong
Chen, Gang
Sun, Chaoyang
Mills, Gordon B. http://orcid.org/0000-0002-0144-9614
Funding for this research was provided by:
CU | National Cancer Institute, Cairo University (CA209988, CA253472, CA217842)
Susan G. Komen (SAC11005)
Dr. Miriam and Sheldon G. Adelson Medical Research Foundation
Article History
Received: 20 June 2023
Revised: 12 July 2023
Accepted: 27 July 2023
First Online: 4 August 2023
Competing interests
: GBM SAB/Consultant: AstraZeneca, BlueDot, Chrysallis Biotechnology, Ellipses Pharma, ImmunoMET, Infinity, Ionis, Lilly, Medacorp, Nanostring, PDX Pharmaceuticals, Signalchem Lifesciences, Tarveda, Turbine, Zentalis Pharmaceuticals; Stock/Options/Financial: Catena Pharmaceuticals, ImmunoMet, SignalChem, Tarveda, Turbine; Licensed Technology: HRD assay to Myriad Genetics, DSP patents with Nanostring. No competing interests were declared by the other authors.